In our cohorts, we found a significantly higher frequency of IDH1/2/TET2 mutations in “APL-like” NPM1m AML (almost all cases bearing one such mutant) and a significantly higher frequency of DNMT3A mutations in “non-APL-like” NPM1m AML. The gene discussed is TET2; the disease is acute myeloid leukemia.